GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Obinutuzumab injection (GAZYVA)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug1 sources available - open source summaries, references and comparisons

Gazyva

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - Gazyva

Product / population
GAZYVA intravenous therapy; distinguish oncology tumor-lysis risk from other indications.
Renal measure
Renal impairment as tumor-lysis risk; renal pharmacokinetic limits.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

In CLL/NHL, impaired renal function increases tumor-lysis risk and requires the source's prophylaxis and close monitoring of fluid balance, electrolytes and renal function. Do not translate renal-response endpoints from lupus-nephritis trials into a renal dose-adjustment schedule. Mild or moderate impairment did not produce a clinically meaningful pharmacokinetic change in the selected analysis; severe impairment has not been formally characterized. These are risk and evidence statements, not a universal severe-impairment or dialysis regimen.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/gazyva-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

GlobalRPh RX List

GlobalRPh RX List - Gazyva

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

GAZYVA intravenous therapy; distinguish oncology tumor-lysis risk from other indications.

Renal method: Renal impairment as tumor-lysis risk; renal pharmacokinetic limits.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - Gazyva
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/gazyva-drug/

Exact product and population

GAZYVA intravenous therapy; distinguish oncology tumor-lysis risk from other indications.

RDM39-SCOPE-obinutuzumab-gazyva · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Gazyva

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · GAZYVA intravenous therapy; distinguish oncology tumor-lysis risk from other indications.

Renal method: Renal impairment as tumor-lysis risk; renal pharmacokinetic limits.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

In CLL/NHL, impaired renal function increases tumor-lysis risk and requires the source's prophylaxis and close monitoring of fluid balance, electrolytes and renal function. Do not translate renal-response endpoints from lupus-nephritis trials into a renal dose-adjustment schedule. Mild or moderate impairment did not produce a clinically meaningful pharmacokinetic change in the selected analysis; severe impairment has not been formally characterized. These are risk and evidence statements, not a universal severe-impairment or dialysis regimen.

RDM39-rxlist-obinutuzumab-gazyva-72807d0424-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/gazyva-drug/
Retrieved
2026-09-07
Renal-function method
Renal impairment as tumor-lysis risk; renal pharmacokinetic limits.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
efc3e18400de3abf0d29ab601cc69fd547f7d229a2b57e29c3b0bdab19d0022a

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/gazyva-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
9860bdbed44fd6087eeecb518451bb4bfb938ca59eab8e3efefbe9b818b9a998
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report